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1128Intermediate-Dose versus Low-Dose
Cyclophosphamide and Granulocyte
Colony-Stimulating Factor for Peripheral Blood
Stem Cell Mobilization in Patients with Multiple
Myeloma Treated with Novel Induction Therapies
Mehdi Hamadani,1 S. Thomas Kochuparambil,2 Salman Osman,1 Aaron Cumpston,1
Sonia Leadmon,1 Pamela Bunner,1 Kathy Watkins,1 Devi Morrison,2 Ethan Speir,2
David DeRemer,2 Vamsi Kota,2 Anand Jillella,2 Michael Craig,1 Farrukh Awan2Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide (ID-CY) and gran-
ulocyte colony-stimulating factor (G-CSF) has been shown to be more efficacious, albeit more toxic, than
low-dose cyclophosphamide (LD-CY) mobilization regimens in patients with multiple myeloma treated
with conventional therapies. However, the relative importance of cyclophosphamide dose intensity in pe-
ripheral blood progenitor cell mobilization after novel induction regimens is not known. Herewe report mo-
bilization outcomes of 123 patients who underwent transplantation within 1 year of starting induction
chemotherapy with novel agents. We compared consecutive patients undergoing mobilization with ID-
CY/G-CSF (3-4 g/m2) at one institution (n5 55) with patients receiving LD-CY/G-CSF (1.5 g/m2) at a differ-
ent transplantation center (n5 68). At baseline, the 2 groups were well balanced, except for more frequent
previous lenalidomide use in the ID-CY group (P 5 .04). Compared with LD-CY, ID-CYuse was associated
with higher median peak PB CD341 cell count (35/mL versus 160/mL; P\.001), CD341 cell yield on day 1 of
collection (2.6 106/kg versus 11.7 106/kg, P#.001), and total CD341 cell yield (7.5 106/kg versus 16.6
 106/kg; P # .001). Six patients in the LD-CY group had mobilization failure, compared with no patients in
the ID-CY group. A significantly higher proportion of patients in the LD-CY group (P\.001) were unable to
collect$5  106/kg and$10  106/kg CD341 cells. Neutrophil and platelet engraftment were significantly
faster in the ID-CY group, likely because of higher infused CD341 cell doses. In conclusion, compared with
LD-CY, ID-CY produced a more robust peripheral blood progenitor cell mobilization and significantly re-
duced the rates of mobilization failure. These data caution against the use of LD-CY–containing mobilization
strategies in patients with multiple myeloma undergoing stem cell collection after novel induction regimens.
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Mobilization of peripheral blood progenitor cells
(PBPCs) for HDT and autologous HCT can be
accomplished using cytokines, most commonly
granulocyte colony-stimulating factor (G-CSF), either
alone or in combination with chemotherapy or
plerixafor [3,4]. There is little consensus about the
optimal method for PBPC mobilization in patients
with MM, although there is a growing recognition
of suboptimal mobilization outcomes of certain
subgroups of patients with MM mobilized with
G-CSF alone [4,5]. Within this context, the adverse
impact of previous lenalidomide therapy on PBPC
mobilization is well documented; with up to 40% of
patients with MM treated with lenalidomide-based
induction chemotherapies not collecting $2  106
Biol Blood Marrow Transplant 18:1128-1135, 2012 1129Evaluation of Cyclophosphamide Dose in PBPC MobilizationCD341 cells/kg when mobilized with G-CSF alone
[6-8]. In contrast, mobilization with chemotherapy
(mostly cyclophosphamide) in addition to G-CSF
has been shown to improve PBPC collection yield
and reduce mobilization failure rates compared with
G-CSF alone [9]. Limited retrospective data suggest
that cyclophosphamide may overcome the effects of
previous lenalidomide exposure on PBPC mobiliza-
tion in patients with MM [10].
The cyclophosphamide doses used for mobiliza-
tion of PBPCs in patients with MM have ranged
from 1 g/m2 up to 7 g/m2 in previous studies. Several
studies have assessed the relative impact of cyclo-
phosphamide dose intensity on PBPC mobiliza-
tion in patients with MM treated with conventional
chemotherapy regimens [11-14]. In general, PBPC
mobilization with high-dose cyclophosphamide
(HD-CY; 7 g/m2) plus G-CSF was found to be signif-
icantly more toxic compared with intermediate-dose
cyclophosphamide (ID-CY; 3-4 g/m2) and G-CSF,
with no convincing evidence of superior efficacy
[11,15]. Studies comparing mobilization with ID-CY
plus G-CSF with low-dose cyclophosphamide (LD-
CY; 1-2 g/m2) plus G-CSF reported higher total
CD341 cell yield with ID-CY, but at the cost of higher
toxicity. However, no significant difference in mobili-
zation failure rates between ID-CY and LD-CYmobi-
lization has been reported [13,14]. Whether the lack
of a clear difference in efficacy between ID-CY and
LD-CY in patients with MM receiving conventional
induction regimens still holds in the era of novel
induction therapies is not known. Determining the
cyclophosphamide dose with the best risk/benefit ratio
for PBPC mobilization is critical to assessing the
efficacy of novel mobilization regimens against
chemotherapy-based mobilizing strategies. Here we
report our retrospective data comparing the efficacy
and toxicity of PBPC mobilization with G-CSF and
either ID-CY or LD-CY in patients with MM receiv-
ing novel induction regimens.PATIENTS AND METHODS
Patient Population
A total of 123 consecutive adult patients with MM
undergoing HDT and autologous peripheral blood
HCT after PBPC mobilization with cyclophos-
phamide plus G-CSF at Georgia Health Sciences
University (GHSU) or West Virginia University
Hospitals (WVUH) were included in this study. All
patients underwent a planned, single autologous
transplantation within 1 year of starting an induction
chemotherapy regimen containing at least one novel
agent (ie, thalidomide, lenalidomide, or bortezomib)
between January 2003 and February 2011. Patients
meeting these criteria and undergoing mobilizationwith cyclophosphamide 1.5 g/m2 and G-CSF consti-
tuted the LD-CY group, and those receiving cyclo-
phosphamide 3-4 g/m2 and G-CSF during the same
period formed the ID-CY group. The study was
approved by the Institutional Review Board and
Protocol Review and Monitoring Committee at
GHSU and WVUH.
PBPC Mobilization and Collection
ID-CY was used for PBPCmobilization at GHSU.
Cyclophosphamidewas administered as a 3-hour i.v. in-
fusion at a dose of 1.5 g/m2/day in 11 patients and 2 g/
m2/day in 44 patients on days 1 and 2, along with
MESNA. All patients received antiemetic prophylaxis
with ondansetron 20 mg i.v. 30 minutes before chemo-
therapy and hydration with 1,000 mL of normal saline
before chemotherapy. G-CSF (10 mg/kg/day subcuta-
neously) was started on day 13 and continued until
the completion of apheresis. All patients in the ID-CY
arm received antimicrobial prophylaxis with levofloxa-
cin, acyclovir, and fluconazole. At WVUH, LD-CY
was used for PBPC mobilization during the study
period, as described previously [16,17]. In brief,
cyclophosphamide was administered at a uniform dose
of 1.5 g/m2 i.v. over 2 hours on day 1. All patients
received antiemetic prophylaxis with ondansetron 24
mg orally 1 hour before chemotherapy, along with
hydration with 500 mL of normal saline before and
after chemotherapy. G-CSF (10 mg/kg/day s.c.) was
started on day 18 and continued until the completion
of apheresis. No antimicrobial prophylaxis was used in
the LD-CY group.
Peripheral blood CD341 cell count was measured
daily when patients’ white blood cell count recovered
to $4,000/mL or from day 112 onward (whichever
occurred first). When the peripheral blood CD341
cell count was $10/mL, apheresis was started. All
collections were performed with a COBE Spectra
Apheresis System (CaridianBCT, Lakewood, CO),
processing 3 to 4 blood volumes. It is the institutional
policy at both transplantation centers to routinely tar-
get collection of a sufficient number of CD341 cells
(ie, a minimum of 5 106 CD341 cells/kg and a target
of$ 10 106 CD341 cells/kg) to administer 2 rounds
of HDT and autologous HCT. (None of the patients
at either transplantation center underwent a planned
tandem autograft, however.) Measurements of periph-
eral blood CD341 cell count and CD341 cell content
of the apheresis product were performed at the GHSU
HLA Laboratory and the WVUH Flow Cytometry
Laboratory. A FACSCanto II flow cytometer (BDBio-
sciences, Sparks, MD) was used for all analyses. Lysed
and washed RBC samples were used for CD341 cell
enumeration with PE-labeled, 8G12 clone immuno-
globulin G1 (BD Biosciences) based on International
Society of Hematotherapy and Graft Engineering
guidelines [18]. The final products were cyropreserved
1130 Biol Blood Marrow Transplant 18:1128-1135, 2012M. Hamadani et al.in 10% DMSO using a controlled-rate freezer and
stored in liquid nitrogen.
Transplantation Procedure and Supportive Care
All patients received uniform conditioning with
melphalan 200 mg/m2 (reduced to 140 mg/m2 in
patients with renal insufficiency) on day -2, followed
by infusion of autologous PBPCs on day 0. All patients
received posttransplantation growth factor support
(G-CSF 5 mg/kg), along with fungal (fluconazole),
herpes zoster/herpes simplex (acyclovir or valacyclo-
vir), and bacterial prophylaxis (ciprofloxacin or levo-
floxacin) in accordance with institutional guidelines.
The time of neutrophil engraftment was considered
the first of 3 successive days with an absolute neutro-
phil count $0.5  109/L after a posttransplantation
nadir. The time of platelet engraftment was considered
the first of 3 consecutive days with a platelet count
$20  109/L, in the absence of platelet transfusion
in the preceding 7 days.
Statistical Analysis
Baseline categorical variables were compared
using the c2 test, and continuous variables were com-
pared using the Wilcoxon rank-sum test or 2-sample
t-test as appropriate. Successful mobilization was
defined as a total of $2  106 CD341 cells/kg patient
body weight in the final product. ‘‘Good mobilizers’’
were defined as patients collecting $5  106 CD341
cells/kg in 1-2 days, as described previously [4]. To
account for differences in the number of collection
days across patients, data on peak peripheral blood
CD341 cell count and CD341 stem cell collection
on day 1 only were analyzed. Nonrelapse mortality
(NRM) was defined as any death without evidence
of disease relapse or progression. Overall survival
(OS) and progression-free survival (PFS) were esti-
mated using the Kaplan-Meier method. OS was de-
fined as the time from transplantation to death from
any cause, and surviving patients were censored at
last follow-up. PFS from transplantation was calcu-
lated using death and disease progression and/or
relapse as events. OS and PFS data were analyzed
using the log-rank test. All P values were 2-sided.
Variables associated with OS and PFS analyses were
run using Cox proportional hazard regression. Vari-
ables that demonstrated an association (P # .10)
were then entered into a multivariate analysis.
Analyses were performed using SPSS 13 (SPSS Inc,
Chicago, IL).RESULTS
Patient Characteristics
The baseline characteristics of the 123 consecutive
patients included in this analysis are presented inTable 1. Sixty-eight patients underwent mobilization
with LD-CY, and the other 55 patients received ID-
CY. The 2 groups did not differ significantly in terms
of patient age, sex, Durie-Salmon stage at diagnosis,
cytogenetic risk, number of previous therapies, overall
bonemarrow cellularity before transplantation, degree
of bone marrow involvement with clonal plasma cells,
and remission status before transplantation. The
median Karnofsky performance score (KPS) was
significantly higher in the LD-CY group, however;
there was no difference in the baseline Hematopoietic
Cell Transplantation Comorbidity Index between the
2 groups. Previous radiotherapy was more frequent in
the ID-CY group (18.1% versus 32.2%); however, this
difference was not statistically significant. The ID-CY
group also had a higher proportion of African-
American patients, as well as more frequent lenalido-
mide exposure before mobilization (40% versus 22%;
P 5 .04).
Efficacy Characteristics
The patients in the LD-CY group started apheresis
at a mean of 12.06 days (median, 12 days; range, 11-14
days) after cyclophosphamide administration, com-
pared with a mean of 12.61 days (median, 12 days;
range, 11-15 days; P \ .001) in the ID-CY group.
The total CD341 cell yield was significantly higher
in the ID-CY group (median collection, 16.6 
106 cells/kg versus 7.5  106 cells/kg; P \ .001)
(Table 2). To account for differences in the number
of collection days across patients, we compared peak
peripheral blood CD341 cell count and CD341 cell
collection on day 1 of apheresis only. Mobilization
with ID-CY was associated with significantly higher
peak peripheral blood CD341 cell count (P\ .0001)
and day 1 CD341 cell count (P\ .001). PBPC mobi-
lization failure was significantly more common in the
LD-CY group (8.8% versus 0%; P 5 .03). As detailed
in Table 2, ID-CY was significantly superior to LD-
CY in the majority of the mobilization efficacy param-
eters analyzed, including the number of patients
collecting $2 million CD341 cells/kg on day 1, num-
ber of patients collecting a total of$5 and$10million
CD341 cells/kg, and the proportion of patients requir-
ing more than 2 apheresis sessions. There was no sig-
nificant difference between the 2 groups in terms of
total number of apheresis sessions and the number of
patients meeting the definition of a good mobilizer as
defined by Wood et al [4].
We next assessed the efficacy of mobilization in the
subgroup of patients who received lenalidomide before
transplantation. Fifteen patients in the LD-CY group
and 22 patients in the ID-CY group had received
a previous lenalidomide-based regimen (P 5 .04).
Three patients (20%) in the LD-CY group with previ-
ous lenalidomide treatment experienced mobilization
failure, compared with none in the ID-CY group
Table 1. Patient Characteristics at the Time of Transplantation
Mobilization Strategy
LD-CY (n 5 68) ID-CY (n 5 55) P value
Age, years, median (range) 57 (37-70) 59 (35-75) .35
Male sex, n (%) 44 (64.7) 32 (58.1) .57
Race, n (%)
Caucasian 65 (95.5) 31 (56.3) <.001
African American 2 (3) 23 (41.8)
Asian 1 (1.5) 1 (1.9)
Durie-Salmon stage, n (%)
1 1 (1.5) 3 (5.4) .59
2 19 (28) 15 (27.2)
3 46 (67.5) 37 (67.2)
Missing 2 (3) —
International Staging System, n (%)
I 2 (3) 26 (47) —a
II 11 (16) 14 (25)
III 10 (15) 7 (13)
Missing 45 (66) 8 (25)
Previous radiation therapy, n (%) 22 (32.3) 10 (18.1) .06
Isotype, n (%)
IgG 34 (50) 44 (80) .01
IgA 23 (33.8) 7 (12.6)
IgD 1 (1.5) 1 (1.9)
Nonsecretory 2 (3) 1 (1.9)
Light chain only 8 (11.7) 2 (3.6)
Median time from diagnosis to transplantation, days (range) 247 (124-1919) 245 (129-2051) .65
Cytogenetic risk, n (%)b
Standard risk 65 (95.5) 47 (85.5) .69
High risk 3 (4.4) 3 (5.4)
Missing — 5 (9)
Pretransplantation bone marrow cellularity, %, mean/median (range)c 47/50 (5-90) 42/40 (10-100) .19
Pretransplantation bone marrow core plasma cell, %, mean/median (range)c 15.5/10 (0-70) 10.8/5 (0-63) .13
Pretransplantation bone marrow aspirate plasma cell, %, mean/median (range) 10.8/3 (0-73) 8/5 (0-32) .30
Previous therapies, n (%)d
Bortezomib 31 (45.5) 30 (54.5) .24
Thalidomide 38 (55.8) 25 (45.4)
Lenalidomide 15 (22) 22 (40) .04
Previous lines of therapy, n, mean/median (range) 1.37/1 (1-4) 1.44/1 (1-4) .58
Pretransplantation status, n (%)
Complete remission + very good partial response 24 (35) 14 (25) .29
Partial response 32 (47) 36 (65)
Less than partial response 12 (17) 5 (9)
KPS, median (range) 90 (70-100) 80 (60-100) .001
Hematopoietic Cell Transplantation Comorbidity Index, median (range) 1 (0-5) 1 (0-5) .90
aP value not calculated because of missing data.
bHigh-risk cytogenetics defined as hypodiploidy or deletion 13 on conventional cytogenetics or presence of t(4;14), t(14:16),217p on fluorescent in situ
hybridization and/or conventional cytogenetics. All other cytogenetic abnormalities were considered standard risk.
cAll bone marrow assessments were performed before stem cell mobilization.
dPercentages do not add up 100% because some patients received more than one novel agent either in combination or during different lines of therapy.
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of lenalidomide-treated patients in the ID-CY group
were able to collect $5 million CD341 cells/kg
(100% versus 73.3%; P 5 .02) and $10 million
CD341 cells/kg (77.2% versus 26.6%; P 5 .006),
and significantly fewer patients in the ID-CY group
required more than 2 apheresis sessions (22.7% versus
73.3%; P5 .006). All patients who failed PBPCmobi-
lization with ID-CY subsequently underwent success-
ful bone marrow harvest or remobilization with
AMD3100/G-CSF.Toxicity and Supportive Care
Four patients (5.8%) in the LD-CY group and
9 patients (16.3%) in the ID-CY group experiencedan episode of febrile neutropenia (P 5 .08)
(Table 3). There was no significant difference be-
tween the 2 groups in the use of i.v. antibiotics
(7.3% versus 16.3%; P5 .11). Hospitalization was re-
quired in 10.2% of the patients in the LD-CY group,
comparedwith 20%of patients in the ID-CY group (P
5 .20). There was a trend toward longer hospital stays
in the ID-CY group (median, 4 days versus 3 days;
P 5 .07). Compared with the LD-CY group, signifi-
cantly more patients in the ID-CY group required
packed RBC (8.8% versus 34.5%; P 5 .001) and
platelet transfusions (2.9% versus 21.8%; P 5 .003)
between day 1 of cyclophosphamide administration
and completion (or termination) of PBPC collection.
There were no mobilization-related deaths or inten-
sive care unit admissions in either group.
Table 2. Mobilization Outcomes According to Cyclophosphamide Dose
LD-CY (n 5 68) ID-CY (n 5 55) P value
Peak peripheral blood CD34+ cell count, m/L, mean/median (range) 56.8/35 (6-309) 255.4/160 (19-1961) <.001
CD34+ cells  106/kg collected on day 1, mean/median (range) 4.05/2.6 (0-15) 16/11.7 (0-61) <.001
Total CD34+ cells  106/kg collected, mean/median (range) 7.8/7.5 (0-18) 24.9/16.6 (2-82) <.001
Total number of apheresis sessions, mean/median (range) 2.49/2 (1-5) 2.2/2 (1-6) .25
Mobilization failures, n (%)a 6 (8.8) 0 (0) .03
Patients collecting $2  106 CD34+ cells/kg on day 1, n (%) 41 (60.3) 48 (87.3) .001
Patients collecting $5  106 CD34+ cells/kg, n (%) 47 (69.1) 53 (96.4) <.001
Patients collecting $10  106 CD34+ cells/kg, n (%) 22 (32.3) 43 (78.1) <.001
Patients requiring more than 1 apheresis session, n (%) 56 (82.3) 53 (96.4) .02
Patients requiring more than 2 apheresis sessions, n (%) 30 (44.1) 12 (21.8) .01
Good mobilizers, n (%)b 30 (63.8) 42 (79.2) .12
aMobilization failure is defined as a total CD34+ cell yield of <2  106 cells/kg.
bGood mobilizers are defined as patients collecting $5  106 CD34+ cells/kg in #2 days.
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All patients proceeded to HDT with melphalan
and autologous HCT, including the 6 patients in the
LD-CY group with mobilization failure (who subse-
quently underwent bone marrow harvest or remo-
bilization with AMD3100/G-CSF). Patients in the
ID-CY group received a significantly higher median
CD341 cell dose (8.1  106 cells/kg versus 4.8  106
cells/kg; P \ .001). The median time to neutrophil
engraftment was significantly shorter in the ID-CY
group (10 days [range, 8-15 days] versus 14 days
[range, 11-35 days]; P\ .001). Similarly, the median
time to platelet engraftment was significantly shorter
in the ID-CY group (17 days [range, 8-40 days] versus
18 days [range, 9-53 days]; P 5 .02). The median
follow-up of the surviving patients was 29.5 months.
The 3-year PFS was 44% for the LD-CY group and
40% for the ID-CY group (P 5 .62). The 3-year
OS was significantly better in the ID-CY group
(84% versus 68%; P 5 .008) (Figure 1). On multivar-
iate analysis, KPS (hazard ratio [HR], 0.93; 95% con-
fidence interval [CI], 0.87-0.99; P 5 .02), infused
CD341 cell dose (HR, 0.72; 95% CI, 0.53-0.97;
P 5 .03), and cyclophosphamide dose (HR, 18.2;
95% CI, 1.5-212.7; P 5 .02), were variables signifi-
cantly associated with OS. The day-100 NRM was
1.8% (n 5 1) for the ID-CY group and 2.9% (n 5 2)
for the LD-CY group (P5 .68), and the corresponding
3-year NRM rates were 1.8% (n 5 1) and 10.2%
(n 5 7) (P 5 .058). The causes of NRM in the LD-
CY group included gram-negative sepsis before day
100 (n 5 1), pneumonia before day 100 (n 5 1), cere-
brovascular accident (n5 2), heart disease (n5 1), sec-
ond malignancy (n 5 1), and unknown (n 5 1). The
cause of NRM in the ID-CY group was sepsis before
day 1100.DISCUSSION
In this study, we analyzed the relative importance
of cyclophosphamide dose intensity on PBPC mobili-zation outcome in patients with MM undergoing au-
tologous HCT after novel induction therapies and
found several interesting results. First, our data sug-
gest that a higher cyclophosphamide dose is associated
with a lower rate of PBPC mobilization failure. Sec-
ond, with higher cyclophosphamide dose, significantly
more patients are able to collect a sufficient number of
CD341 cells to potentially undergo 2 rounds of HDT.
Third, it appears that this higher dose, while requiring
more transfusion support, was not clearly associated
with significant increases in hospitalization and the
need for i.v. antibiotics.
The cyclophosphamide doses used for PBPC mo-
bilization in patients withMM varied widely (range, 1-
7 g/m2) in previous studies. Compared with ID-CY
plus G-CSF, HD-CY for PBPC mobilization in pa-
tients with MM treated with conventional chemother-
apy regimens is significantly more toxic, without
convincing evidence of superior efficacy [11,15].
Previous studies comparing ID-CY plus G-CSF and
LD-CY plus G-CSF have reported higher total
CD341 cell yield with ID-CY, but at the cost of higher
toxicity [13,14]. Whether the lack of a clear difference
in efficacy between ID-CY and LD-CY in patients
with MM treated with conventional chemotherapy
regimens remains true in the era of novel agents is un-
known.
In previous retrospective studies of patients with
MM treated with conventional chemotherapy regi-
mens (mostly combinations of vincristine, adriamycin,
and dexamethasone), PBPC mobilization with ID-CY
plus G-CSF produced higher peak peripheral blood
CD341 cell counts [14] and higher total CD341 cell
yield [13,14] compared with LD-CY plus G-CSF,
but with no difference in the rate ofmobilization failure
as defined in our study. In contrast, we report here (in
the largest study to date, to our knowledge) that in the
era of novel therapies, LD-CY–based mobilization is
associated with a significantly higher rate of stem cell
mobilization failure. This is especially noteworthy,
because the 2 groups in our study were closely matched
for parameters that can potentially affect PBPC
Table 3. Toxicity and Supportive Care
LD-CY
(n 5 68)
ID-CY
(n 5 55) P value
Neutropenic fever, n (%)a 4 (5.8) 9 (16.3) .08
Need for i.v. antibiotics, n (%) 5 (7.3) 9 (16.3) .11
Packed RBC transfusion, n (%) 6 (8.8) 19 (34.5) .001
Platelet transfusion, n (%) 2 (2.9) 12 (21.8) .003
Hospitalization, n (%) 7 (10.2) 11 (20) .20
Days of hospitalization,
mean/median (range)
6/3 (1-5) 11/4 (1-9) .07
aA single episode of fever of $101F, or 2 episodes of fever >100.4F
at least 1 hour apart in a patient with an absolute neutrophil count
of <500/mL.
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therapy, number of lines of previous therapy, time be-
tween diagnosis and transplantation, pretransplanta-
tion bone marrow cellularity, and degree of bone
marrow plasmacytosis, except for a significantly higher
previous lenalidomide exposure in the ID-CYgroup. In
line with conventional chemotherapy-era data, in the
present study, ID-CY produced higher peak peripheral
bloodCD341 cell counts anda significantly higher total
CD341 cell yield. More importantly, a significantly
higher proportion of ID-CY patients were able to
meet our institutional goals of minimum ($5 million
CD341 cells/kg) and target ($10 million CD341
cells/kg)CD341 cell yieldwithout theneed for a greater
number of apheresis sessions. Although we acknowl-
edge that optimal CD341 collection yield (and thus
the optimal collection target) is controversial, similar
minimum and target levels with slight variations have
been used by other investigators [4,19,20] and
international myeloma working group guidelines
[5,21].
The significantly higher requirements for packed
RBC and platelet transfusion support in our ID-
CY group is in agreement with the majority of previ-
ous studies using similar doses of cyclophosphamide
[13,19,22]. However, unlike previous studies in whichSolid Curve- LD-CY
Interrupted curve- ID-CY
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Figure 1. Kaplan-Meier curves of PFS (A) andOS (B) relative to cyclophospham
ID-CY.ID-CY was associated with significantly higher rates
of febrile neutropenia, i.v. antibiotic use, and need for
hospitalization [13,14,19] compared with LD-CY,
these rates were not significantly higher in our ID-
CY group, with only a trend toward longer hospitaliza-
tion seen in this group (P5 .07). It is possible that our
analysis was not sufficiently powered to detect a differ-
ence in infectious complications, however. In contrast
to previous studies, our ID-CY patients were routinely
given prophylactic antibiotics, which might have re-
duced the rates of febrile neutropenia and subsequent
need for i.v. antibiotics and hospitalization.
Previous therapy with lenalidomide is known to
negatively affect PBPC mobilization [7,8]. In a study
of 28 patients with MM treated with a combination
of dexamethasone, clarithromycin, and lenalidomide,
Mark et al [10] reported sufficient stem cell collection
for 2 autologous HCTs from all patients mobilized
with cyclophosphamide (3 g/m2) plus G-CSF versus
adequate collection in only 33% of patients mobilized
with G-CSF alone. This finding suggests that
this approach can potentially overcome the impaired
PBPC mobilization associated with lenalidomide
[5]. Our study provides further data indicating that
although ID-CY plus G-CSF can potentially over-
come lenalidomide-related impairment of PBPC
mobilization, this effect is probably dose-related, and
LD-CY–containing regimens remain associated with
a high risk of mobilization failure and a significantly
lower stem cell yield.
DiPersio et al [23] in a phase III study, found that
AMD3100 (plerixafor) plus G-CSF was significantly
superior to G-CSF plus placebo for PBPC mobiliza-
tion in patients with MM. To the best of our knowl-
edge, no prospective trials comparing AMD3100
plus G-CSF and cyclophosphamide plus G-CSF
have been published to date. Determining the cyclo-
phosphamide dose with the best risk/benefit ratio for
PBPC mobilization is critical for prospectively0
5
0
5
0
0 365 730 1095 1460 1825
Days from Transplantation
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ide dose intensity. The solid curve represents LD-CY; the dashed curve,
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lization regimens against an optimally dosed
chemotherapy-based mobilizing strategy. Shaugh-
nessy et al [19] retrospectively compared mobilization
with AMD3100 plus G-CSF with cyclophosphamide
(3-5 g/m2)-based chemomobilization. There was no
significant difference between the 2 groups of patients
in terms of total CD341 cells collected, mobilization
costs, and clinical outcomes. Cyclosphosphamide mo-
bilization was associated with higher rates of hospital-
ization, however. Comparison of these mobilization
strategies merits prospective investigations.
A surprising finding of the present study is the
superior OS of the ID-CY group. As far as we know,
no previous studies have reported a survival benefit
attributable to PBPC mobilization strategy (except for
the known benefit of peripheral blood autografts over
bone marrow autografts). Although cyclophosphamide
has activity against MM, we caution against overinter-
preting the OS benefit seen in the ID-CY group in
this retrospective study. It is possible that this benefit
is due largely to the significantly higher CD341 cell
dose infused in these patients, with resulting faster
neutrophil engraftment and reduced infectious compli-
cations. Improved survival outcomes in patients with
MM receiving a higher infused CD341 cell dose have
been reported by others as well [24]. Althoughwe noted
a trend toward a higher 3-year NRM in our LD-CY
group, the majority of these patients did not die due
to infectious complications. It is also possible that dif-
ferences in posttransplantation maintenance strategies,
imbalances in access to investigational therapies, or
unknown biological differences might contribute to
this survival difference in our 2 groups.
In conclusion, the present study found robust
mobilization of PBPCs in patients with MM treated
with novel agents, including the challenging subgroup
of lenalidomide-treated patients, with an ID-CY plus
G-CSF regimen, with no significant increase in infec-
tious complications or morbidity. Our data caution
against the use of LD-CY–containing mobilization
regimens in patients with MM receiving induction
therapy with novel agents.ACKNOWLEDGMENTS
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